| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 4.1 | 7.2 | 6.7 |
| Other income | 0.0 | 0.1 | 0.0 |
| Total income | 4.2 | 7.3 | 6.7 |
| Profit before exceptional items & tax | -1.8 | -1.4 | -7.2 |
| Exceptional items | 4.2 | -0.1 | 0.0 |
| Profit before tax | 2.4 | -1.5 | -7.2 |
| Net profit | 1.9 | -1.1 | 5.3 |
| Operating margin | 57.1% | -20.5% | -107.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -64.20% |
|---|---|
| Revenue, year on year | -38.80% |
| Operating profit, year on year | +75.00% |
| Operating profit, quarter on quarter | -20.00% |
BSE results filing, NSE: PHARMAID. Figures extracted from the filing.
Pharmaids Pharmaceuticals Ltd: key numbers
- Share price
- ₹30.40
- Market cap
- ₹107.2 Cr
- Revenue (annual)
- ₹27.88 Cr
- Net profit (annual)
- ₹-11.72 Cr
- P/E (TTM)
- -23.5×Sector 50.4×
- Promoter holding
- 32.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Pharmaids Pharmaceuticals Ltd
All →Pharmaids Pharmaceuticals Legal & Regulatory
Pharmaids Pharmaceuticals filed legal complaints against Anugraha Chemicals for dishonoured cheques totalling ₹2.63 Crore in outstanding dues from a disinvestment agreement.
- Value
- ₹2.63 Cr
Pharmaids Pharmaceuticals Annual General Meeting
Pharmaids Pharmaceuticals held its 37th AGM via video conference on 11 Sept 2026. Four resolutions including adoption of FY26 financials and related-party-transaction approvals were tabled.
Pharmaids Pharmaceuticals Promoter Buying (Off-Market)
KMP Prasanna Subramanya Bhat acquired 17,291 shares of Pharmaids Pharmaceuticals Ltd via a gift from an immediate relative. This off-market transfer is an insider disclosure.
- Promoter stake change
- +0.04%
Pharmaids Pharmaceuticals Q4 FY26 Results: Net Loss of ₹1.1 Cr, Loss Narrows
Pharmaids Pharmaceuticals Ltd reported revenue from operations of ₹7.2 Cr (+50.0% YoY) and a net loss of ₹1.1 Cr for Q4 FY26.
- Key figure
- Net loss ₹1.1 Cr